This is an academic paper that provides commentary on the racial disparities in access to medications for opioid use disorder (MOUD), especially buprenorphine, and proposes short- and long-term solutions to address racial and socioeconomic disparities in access to MOUD following changes in regulations due to the coronavirus pandemic.